<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04766723</url>
  </required_header>
  <id_info>
    <org_study_id>M602011069</org_study_id>
    <nct_id>NCT04766723</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Efficacy and Safety of NT 201 (Botulinum Toxin) Compared With Placebo for the Treatment of Adult Participants With Essential Tremor in the Arm</brief_title>
  <official_title>Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Period to Investigate the Efficacy and Safety of NT 201 in the Unilateral and Bilateral Treatment of Essential Tremor of the Upper Limb</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merz Pharmaceuticals GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merz Pharmaceuticals GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a single treatment with administration of&#xD;
      NT 201 (botulinum toxin) is superior to placebo (no medicine) for one-sided treatment of&#xD;
      essential tremor in the arm (Unilateral Period). Participants will be assigned to the&#xD;
      treatment groups by chance and neither the participants nor the research staff who interact&#xD;
      with them will know the allocation.&#xD;
&#xD;
      The following treatment cycle will investigate the safety and tolerability of two-sided&#xD;
      treatment with NT 201 (botulinum toxin) (Open Label Bliaterial Period). All participants will&#xD;
      receive NT 201 treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 24, 2021</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from study baseline to Week 6 in maximum tremor amplitude measurement at wrist level during the unilateral treatment period</measure>
    <time_frame>From baseline to week 6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from study baseline to Week 6 in the Essential Tremor Rating Assessment Scale [TETRAS] Performance dominant upper limb [UL] score</measure>
    <time_frame>From baseline to week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from study baseline to Week 6 in TETRAS Activities of Daily Living [ADL] UL score</measure>
    <time_frame>From baseline to week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from study baseline to Week 6 in TETRAS ADL Functional Impact score</measure>
    <time_frame>From baseline to week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject´s Global Impression of Change Scale [GICS] score of motor dominant UL at Week 6</measure>
    <time_frame>Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator´s Global Impression of Change Scale [GICS] score of motor dominant UL at Week 6</measure>
    <time_frame>Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Cycle 2 baseline to Week 6 in TETRAS Performance dominant UL score</measure>
    <time_frame>Week 24 to week 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Cycle 2 baseline to Week 6 in TETRAS Performance subscale score</measure>
    <time_frame>Week 24 to week 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Cycle 2 baseline to Week 6 in TETRAS ADL UL score</measure>
    <time_frame>Week 24 to week 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Cycle 2 baseline to Week 6 in TETRAS ADL Functional Impact score</measure>
    <time_frame>Week 24 to week 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent AEs [TEAEs] related to treatment</measure>
    <time_frame>From baseline to week 36</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Essential Tremor of the Upper Limb</condition>
  <arm_group>
    <arm_group_label>NT 201 (IncobotulinumtoxinA, Xeomin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Unilateral Treatment Period (1 treatment cycle): subjects to receive unilateral intramuscular injection of NT 201 (130-165 units) into muscles of the upper limb.&#xD;
Open Label Bilateral Treatment Period (1 treatment cycle): subjects to receive bilateral intramuscular injection of NT 201 (130-165 units) into muscles of the upper limbs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Unilateral Treatment Period (1 treatment cycle): subjects to receive unilateral intramuscular placebo injection into muscles of the upper limb.&#xD;
Open Label Bilateral Treatment Period (1 treatment cycle): subjects to receive bilateral intramuscular injection of NT 201 (130-165 units per arm) into muscles of the upper limbs.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NT 201</intervention_name>
    <description>Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).</description>
    <arm_group_label>NT 201 (IncobotulinumtoxinA, Xeomin)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Incobotulinumtoxin A</other_name>
    <other_name>IncobotulinumtoxinA</other_name>
    <other_name>Xeomin</other_name>
    <other_name>Botulinum toxin type A (150 kiloDalton), free from complexing proteins</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Score of ≥ 2 (at least 1 cm tremor amplitude) in at least two out of three maneuvers of&#xD;
        test item 4 (upper limb tremor) confirmed by an independent TETRAS expert by means of video&#xD;
        assessment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or presence of day-to-day fluctuations in ET which would jeopardize meaningful&#xD;
             tremor assessment over time, e.g. severe tremor on one day and minimal or no tremor on&#xD;
             another day.&#xD;
&#xD;
          -  Other neurological signs, such as dystonia, ataxia, or parkinsonism, which in the&#xD;
             judgment of the investigator could interfere with the ET diagnosis and/or assessment&#xD;
             of ET in ULs.&#xD;
&#xD;
          -  Tremor types other than ET&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Merz Medical Expert</last_name>
    <role>Study Director</role>
    <affiliation>Merz Pharmaceuticals GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Public Disclosure Manager</last_name>
    <phone>+49 69 1503 0</phone>
    <email>clinicaltrials@merz.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>USF, Department of Neurology, Merz Investigational Site #0010020</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center, Merz Investigational Site #0010269</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Lou Ruvo Center for Brain Health, Merz Investigational Site #0010457</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center, Merz Investigational Site #0010191</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center, Neuroscience Institute, Merz Investigational Site #0010206</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Selkirk Neurology, Merz Investigational Site #0010456</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre, Merz Investigational Site #0010087</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 19, 2021</study_first_submitted>
  <study_first_submitted_qc>February 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tremor</mesh_term>
    <mesh_term>Essential Tremor</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
    <mesh_term>incobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

